ARTICLE SUMMARY:
Tibial nerve stimulation is a physiologically validated but underused therapy for urinary urge incontinence because the delivery model is prohibitive for many patients. BlueWind takes TNS to the next level with an implant that puts the patient in control.
Founded in 2010 by the Israeli incubator Rainbow Medical to develop a neuromodulation therapy for urinary urge incontinence (UUI), BlueWind Medical was shepherded through many technical challenges by founding CEO Guri Oron. When seasoned medtech executive Dan Lemaitre became chairman of the board in 2018 to help fund the company to the next level, he found a start-up with significant differentiation in an existing and underserved urinary urge incontinence market. In May 2022, Lemaitre was successful in helping the company complete a 64 million Series B funding round led by ConvaTec.
